The Broad Institute is at the forefront of biomedical research, employing a diverse array of advanced technologies to enhance our understanding of various diseases and improve patient outcomes. One of the key areas of focus is cancer, where researchers are investigating the underlying mechanisms and applying their findings to develop precision medicine approaches. The institute's work spans multiple disease areas, including cardiovascular disease, diabetes, infectious diseases, and psychiatric disorders, utilizing innovative tools such as chemical biology, drug discovery, and genomics. The integration of data sciences and genetic perturbation technologies allows for comprehensive analysis and manipulation of biological systems, facilitating breakthroughs in understanding complex diseases.

Additionally, the Broad Institute's Spatial Technology Platform exemplifies its commitment to cutting-edge research. This platform leverages spatial transcriptomics and multiplexed immunofluorescence to study gene and protein expression at the single-cell level within their spatial context. By providing full-stack support for spatial studies—from study design to data acquisition and processing—the platform enables researchers to tackle critical biological questions across various models and clinical samples. The active research arm of the Spatial Technology Platform is dedicated to developing novel computational and imaging techniques, further enhancing the institute's capabilities in addressing complex biological challenges.

United States

Broad Institute of MIT and Harvard was launched in 2004 to improve human health by using genomics to advance our understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies.COVID-19: EUA (03/2021) for CRSP SARS-CoV-2 Real-time Reverse Transcriptase-PCR Diagnostic Assay

Broad Institute

Company Details